Clinical trial
AZD6765 for Treatment Resistant Depression
NCT00491686 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00491686 |
|---|---|
| Title | AZD6765 for Treatment Resistant Depression |
| Official title | A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | AZD6765 |
| Enrollment | 34 |
| Start date | Jul 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Jun 26, 2007 |
| Last update posted | Jan 21, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: